A COVID-19 treatment showing early signs of promise is at risk of being overshadowed by the vaccine rollout. The aim of giving a one-time monoclonal antibody treatment is to seize a window of opportunity early in the course of COVID-19. Unlike monoclonal antibodies, convalescent serum includes a range of antibodies. For a treatment showing early promise, there hasn't been much pick up of monoclonal antibodies in COVID-19. What's more, current monoclonal antibody treatments for COVID-19 need to be given by infusion, similar to some chemotherapy agents.

Source: CBC News December 25, 2020 09:00 UTC